Burden of Hodgkin and non-Hodgkin lymphoma in Spain over a 10-year period: productivity losses due to premature mortality.
CONCLUSIONS: Lymphoma represents a significant burden that can be reduced with the implementation of improved diagnosis and treatment methods, which must be taken into account in resource allocation and management policies. PMID: 32450710 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 28, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Elderly individuals with diabetes and foot ulcer have a probability for healing despite extensive comorbidity and dependency.
CONCLUSION: Healing without major amputation was achieved in 84% of surviving patients ≥75 years, despite extensive comorbidity and dependency. PMID: 32448021 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 27, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The burden of productivity loss of U.S. commercially insured patients diagnosed with Dupuytren's disease undergoing collagenase versus fasciectomy treatment.
Conclusion: This study indicates that collagenase vs. fasciectomy treatment may be related to a lower rate of workplace absence and lower indirect cost in a year following the treatment. PMID: 32408788 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 17, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cardiovascular outcome trials of glucose-lowering therapies.
Authors: Khunti K, Davies MJ, Seidu S Abstract Introduction: Early initiated and long-term sustained intensive glucose control is associated with a significantly decreased risk of cardiovascular events and all-cause mortality, over and above the well-established decline in the risk of microvascular disease. Based on the recent cardiovascular outcome trial (CVOT) data, this review focuses on the various benefits of the newer medications with their positioning in the treatment algorithm and explores the place of the older medications in the management of type 2 diabetes mellitus (T2DM).Areas covered: We searched the ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 15, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
Conclusion: The adoption of the SC formulation for rituximab and trastuzumab can generate a greater "value" for both the national healthcare system and the patient compared to an IV formulation. PMID: 32403958 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 15, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Barriers to implementing pharmacoeconomics: interview study.
Conclusion: The current use and impact of pharmacoeconomic evaluations in Jordanian healthcare decision-making is restricted, in part, due to the barriers outlined by the respondents. PMID: 32394752 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 14, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Economic evaluation of a multimodal intervention in pre-frail and frail older people with diabetes mellitus: the MID-FRAIL Project.
Conclusions: The MID-FRAIL intervention programme showed to be the dominant option in comparison with usual care practice. It saved costs to the health care system and achieved worthwhile health gains. This finding should encourage its implementation, at least, in the trial participant countries.Key words: diabetes; T2DM; frailty; older people, health care costs; cost-utility; economic evaluation; multimodal intervention. PMID: 32394757 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 14, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Barriers and facilitators of exploiting the potential of value-added medicines.
Authors: Petykó ZI, Inotai A, Holtorf AP, Brixner D, Kaló Z Abstract Introduction: Pharmaceutical research and development (R&D) is costly and only a minority of patients can access innovative medicines due to affordability constraints. Value added medicines (VAMs) can offer potential benefits at significantly lower R&D costs.Areas covered: VAMs may address different health care needs and problems, including off-label use of medicines, poor patient adherence, problems related to polypharmacy, need for home and/or personalized health care services. However, several barriers prevent societies fr...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 25, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The current state of patient access to new drugs in South Korea under the Positive List System: evaluation of the changes since the new review pathways.
This study aims to provide an up-to-date analysis of the current state of patient access to new drugs in South Korea, focusing on the effect of new review pathways for reimbursement.Methods: We analyzed patients' access to new drugs, listing rate and lead time until listing from marketing authorization. New pathways were defined as "price negotiation waiver", "risk-sharing agreements" and "pharmacoeconomic evaluation exemption".Results: The listing rate for drugs increased after the introduction of the new pathways (93.7% vs. 77.9%, p
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 22, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Comparative Cost-Effectiveness of Amisulpride and Olanzapine in the Treatment of Schizophrenia in China.
Conclusions: Amisulpride is likely to be a cost-effective option with increased effectiveness compared with olanzapine in the treatment of schizophrenia patients in China. PMID: 32293194 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 17, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Predicting SF-6Dv2 utility scores for chronic low back pain using the Oswestry Disability Index and Roland-Morris Disability Questionnaire.
Authors: Poder TG, Carrier N Abstract Background: Cost utility analysis is increasingly used by decision makers in patient management with chronic disease. Generic preference-based measures are used to evaluate disability and health-related quality of life (HRQoL).Objective: To evaluate if Short Form Six Dimensions (SF-6Dv2) is correlated with specific current questionnaires used in chronic low back pain (CLBP) and if a predictive equation of SF-6Dv2 could be established.Methods: Between October 2018 and January 2019, an online survey on CLBP was conducted. HRQoL was measured with two specific questionnaires, i.e. ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 12, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Evaluation of the Cost-Utility of the York Faecal Calprotectin Care Pathway.
Conclusions: The YFCCP demonstrated a QALY benefit when compared with all alternative pathways. PMID: 32249622 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 8, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

"Without data, you're just another person with an opinion".
"Without data, you're just another person with an opinion". Expert Rev Pharmacoecon Outcomes Res. 2020 Apr 06;: Authors: Kolasa K, Goettsch W, Petrova G, Berler A Abstract IntroductionGiveni the recent impressive digital transformation worldwide, the importance of data has reached a new dimension. It is, therefore, provocative to ask whether data can save healthcare systems from bankruptcy.Areas covered: We reviewed published examples in the search for the evidence on how the growing amount of data could change the way we used to assess the value of healthcare technologies, ensuring a more ho...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 8, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The efficacy and economic evaluation of roxadustat treatment for anemia in patients with kidney disease not receiving dialysis.
Conclusion: For the treatment of anemia in Chinese patients with CKD ND, roxadustat is much more effective than a placebo; moreover, it is cost-effective at conventional WTP thresholds. PMID: 32249625 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 8, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries.
Authors: Godman B, McCabe H, D Leong T, Mueller D, Martin AP, Hoxha I, Mwita JC, Rwegerera GM, Massele A, Costa JO, do Nascimento RCRM, Lemos LLP, Tachkov K, Milushewa P, Patrick O, Niba LL, Laius O, Sefah I, Abdulsalim S, Soleymani F, Guantai AN, Achieng L, Oluka M, Jakupi A, Logviss K, Hassali MA, Kibuule D, Kalemeera F, Mubita M, Fadare J, Ogunleye OO, Saleem Z, Hussain S, Bochenek T, Mardare I, Alrasheedy AA, Furst J, Tomek D, Markovic-Pekovic V, Rampamba EM, Alfadl A, Amu AA, Matsebula Z, Phuong TNT, Thanh BN, Chichonyi Kalungia A, Zaranyika T, Masuka N, Olaru ID, Wale J, Hill R, Kurdi A, Timoney A, Campbell S, Meyer ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 4, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis.
Conclusion: The economic model developed provides a robust framework for future analyses assessing the cost-effectiveness of baricitinib for the treatment of RA in specific country settings. PMID: 32212867 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 29, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Effectiveness of non-pharmacological COPD management on health-related quality of life - a systematic review.
Authors: Hindelang M, Kirsch F, Leidl R Abstract INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality worldwide. The chronic progressive disease is accompanied by a high loss of health-related quality of life (HRQoL). The available drugs only have symptomatic effects; therefore, non-pharmacological therapies are essential.Areas covered:This systematic review examines non-pharmacological interventions consisting of pulmonary rehabilitation, physical activity, and training versus usual care or no intervention in COPD using at least one of the following HRQoL measuring ins...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 28, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The evolution of patient-focused drug development and Duchenne muscular dystrophy.
We present Duchenne muscular dystrophy as a case study to illustrate how PFDD is being operationalized by patient groups and regulators using both verbal and written data sources.Expert opinion: PFDD represents the most widespread approach yet to integrate the patient voice as a source of evidence to inform regulatory decision making. Regulatory approvals are just one frontier in drug development. On the horizon remain uncertainties in how patient experience can inform post-marketing surveillance, pricing, reimbursement, and health technology assessment. Patient-input may be particularly crucial to demonstrate the value of...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 28, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Translation and back-translation methodology in health research - a critique.
Authors: Ozolins U, Hale S, Cheng X, Hyatt A, Schofield P Abstract Introduction: While back translation has been widely used in medical research surveying linguistically diverse populations, research literatureoften fails to document this complex translation process. Our study examines inadequacies in the use of back translation, suggests improvements, as well as suggesting where other translation strategies may be more appropriate.Areas covered: This paper cites numerous metastudies showing how back translation is often uncritically adopted in validation of research instruments, pointing to potential methodologica...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 25, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between Marketing Authorization and HTA.
Conclusion: Various different reasons led to the failure of EBAs in the past. Despite different objectives, a better alignment between the requirements and methods in the marketing authorization procedure and the EBA might facilitate the design of pivotal studies, which may be useful in both procedures. PMID: 32043904 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 12, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Factors associated with the healthcare expenditures of patients with multiple sclerosis in urban areas of China estimated by a generalized estimating equation.
Conclusion: This study illustrates the medical costs and burden of MS in Chinese patients and provides real-world data on MS that are essential for the improvement of health policies. PMID: 31984811 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 29, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Disease burden of patients with pemphigus from a societal perspective.
Authors: Brodszky V, Tamási B, Hajdu K, Péntek M, Szegedi A, Sárdy M, Bata-CsörgÅ‘ Z, Kinyó Á, Gulácsi L, Rencz F Abstract Objective: Cost-of-illness studies are widely used for healthcare decision-making; however, no such study is available in pemphigus from the societal perspective. The purpose of this analysis was to estimate annual cost-of-illness per patient with pemphigus from a societal perspective.Methods: Between 2014 and 2017, a multicenter, cross-sectional study was carried out. Consecutive pemphigus patients aged ≥18 years were recruited at all four univ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 26, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Heart failure in the Veneto region of Italy: analysis of therapeutic pathways and the utilization of healthcare resources.
Conclusions: In our study, we observed an under-prescription of recommended drugs for the treatment of HF. Moreover, one out of four HF patients were re-hospitalized for HF-related causes and the healthcare costs related to hospitalization accounted for the great majority of the total healthcare resource costs. PMID: 31971025 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 25, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

How cost-effective are new cancer drugs in the U.S.?
Authors: Lichtenberg FR Abstract Introduction: More than 8 times as many new cancer drugs were approved during 2005-2015 as were approved during 1975-1985 (66 vs. 8). The average annual 2010-2014 growth rate of U.S. cancer drug expenditure was 7.6%. This has contributed to a lively debate about the value and cost-effectiveness of new cancer drugs.Areas covered: We assess the average cost-effectiveness in the U.S. in 2014 of new cancer drugs approved by the FDA during 2000-2014, by performing an original econometric investigation (rather than a literature review) of whether there were larger declines in premature mo...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 9, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Impact of pharmacist-led multidisciplinary medication review on the safety and medication cost of the elderly people living in a nursing home: a before-after study.
In this study, we assessed the impact of multidisciplinary medication review (MMR) for nursing home residents on patient safety and costs incurred by the hospital and the national health service.Methods: Medical files of residents were retrospectively assessed for medications prescribed in the previous six months. A pharmacist reviewed the prescriptions and suggested modifications to the patient's medical team. Patients were followed for six months. Trivalle's ADE geriatric risk score was calculated before and after MMR, as were number of potentially inappropriate medications, and economic impact from the perspective of th...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 6, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cognitive behavior therapy for health anxiety: systematic review and meta-analysis of clinical efficacy and health economic outcomes.
Authors: Axelsson E, Hedman-Lagerlöf E Abstract Introduction: Health anxiety, also known as 'hypochondriasis', is a common, distressing and costly condition that responds to cognitive behavior therapy (CBT) but evidence pertaining to response and remission rates, treatment in routine care, therapist-guided Internet-delivered CBT (ICBT) and health economics has not been systematically reviewed.Areas covered: In this systematic review and meta-analysis we searched PubMed, PsycINFO, and OATD (17/06/2019) for randomized controlled trials (RCTs) comparing CBT to non-CBT controls for health anxiety. Based on 19 RCTs...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 22, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Learning from our mistakes: Using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
Authors: Edwards SE, Morel CM Abstract INTRODUCTION: Governments need to do far more to help curb the emergence and transmission of antibiotic resistance and help protect the efficacy of any new antibiotics that come to market. Industry is an important stakeholder that must be brought on-board such efforts given its influence on the direction and scale of antibiotic sales. Financial incentives supporting industry R&D of novel antibiotics should structurally remove the drivers of superfluous sales and encourage access to newer antibiotics where infections are otherwise resistant to treatment. Indeed the use of p...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 20, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel.
Conclusions: The number of agreements and the allocated budget subject to these agreements increased substantially in recent years. Most agreements are financial-based that, in many cases, shifted the short-term financial risk from health-plans to the industry. PMID: 31825682 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 13, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia.
Conclusions: In Slovenia, time to access to novel anticancer drugs exceeds two years and, more importantly, is equally long for drugs with or without substantial clinical benefit. Integration of the ESMO-MCBS into reimbursement deliberations could improve access to drugs with substantial clinical benefit. PMID: 31826655 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 13, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Consumer Willingness to pay for a hypothetical chikungunya vaccine in Brazil and the implications.
CONCLUSION: This study can contribute to decision-making about potential prices for a chikungunya vaccine once it becomes available in Brazil. We demonstrated the relevance of the anchoring effect as a possible influence applied to the maximum value of the WTP associated with respondents' preference for a new vaccine. Finally, we encourage the development of a chikungunya virus vaccine to benefit the Brazilian population. PMID: 31815561 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 10, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad and the ugly ways.
Authors: Inotai A, Kaló Z Abstract Introduction: There is significant difference in utilisation of patented medicines in the EU, as pharmaceuticals at Western European price levels are usually not cost-effective in Central Eastern European (CEE) countries. The article reviews options to solve the 'financing gap' posed by the challenge of covering patented medicines from more restricted resources in countries with greater unmet medical need.Areas covered: Hidden volume restrictions to patented pharmaceuticals implemented by payers to facilitate financial sustainability may increase European inequity in patien...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 9, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Estimating the money flow in the economy attributed to rotavirus disease and vaccination in the Netherlands using a Social Accounting Matrix (SAM) framework.
Authors: Kotsopoulos N, Haitsma G, Connolly MP, Standaert B Abstract Background: The economics of rotavirus gastroenteritis in infants
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 23, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

What do national pharmacoeconomic guidelines recommend regarding the statistical analysis of trial-based economic evaluations?
Authors: Dongen JMV, El Alili M, Varga AN, Guevara Morel AE, Jornada Ben A, Khorrami M, van Tulder MW, Bosmans JE Abstract Introduction: The statistical quality of many trial-based economic evaluations is poor. When conducting trial-based economic evaluations, researchers often turn to national pharmacoeconomic guidelines for guidance. Therefore, this study reviewed which recommendations are currently given by national pharmacoeconomic guidelines on the statistical analysis of trial-based economic evaluations.Areas covered: 40 national pharmacoeconomic guidelines were identified. Data were extracted on the guidelin...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 19, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Intrinsic properties of medical devices: considerations for economic evaluation.
This study evaluates the generalizability of four device-specific criteria, as recommended by the recent MedtechHTA project, of learning curve, incremental innovation, dynamic pricing, and organizational impact with a broader group of MDs including diagnostics and implantables. The purpose was to determine the applicability of these criteria to a broader range of MDs.Areas Covered: We determined the extent to which these criteria could be applied to each device type and attempted to identify common themes. We performed a literature search using PubMed and Google of a range of devices to understand the clinical significance...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 15, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 Inactivated Varicella-Zoster Vaccine (ZVIN) trial.
CONCLUSION: Both HZ and PHN are associated with considerable disutility in recipients of auto-HSCT. Costs were comparable to published estimates in other immunocompromised subjects.The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT01229267). PMID: 31721601 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 15, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The cost-effectiveness of metformin in pre-diabetics: a systematic literature review of health economic evaluations.
ConclusionILC is cost-effective compared to metformin and, both of them are cost-effective compared to placebo. Metformin may be cost-saving in the short- to medium-term and possibly in the long-term. PMID: 31674846 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 3, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

An assessment of the economic burden of senile chronic diseases in China based on China Health and Retirement Longitudinal Survey.
Conclusions: Relevant results may provide insight into formulating health and labor policies by the Chinese government. The study significance consists of the selection of matching variables and robustness, whereas study limitations include the omission of other important variables. PMID: 31675261 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 3, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Direct cost of Parkinson's disease in a health system with high judicialization: evidence from Colombia.
Conclusions: In the context of high judicialization, patients suffering from PD must increasingly use the judicial system to access treatment. To promote more equitable and efficient access benefit packages, developing countries must consider more thoroughly the needs of these patients. PMID: 31627711 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 21, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost burden of diffuse large B-cell lymphoma.
Authors: Harkins RA, Patel SP, Flowers CR Abstract INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and is a clinically heterogenous disease. Treatment pathways for DLBCL are diverse and integrate established and novel therapies. Areas covered: We review the cost burden of DLBCL and cost-effectiveness of DLBCL management including precision and cellular medicine. We utilized Medical Subject Heading (MeSH) terms and keywords to search the National Library of Medicine online MEDLINE database (PubMed) for articles related to cost, cost burden, and cost-of-illness of DLBCL and...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 20, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Economic evaluations of oral medications for breast cancer treatment in the U.S.: A systematic review with a focus on cost-effectiveness threshold.
Authors: Park SK, Chun HK, Park C Abstract Introduction: With the advent of targeted therapy, the U.S. Food and Drug Administration has recently approved several oral anticancer medications (OAMs) for breast cancer (BC). Despite the improved effectiveness of those OAMs, the high financial burden is an issue. Evidence from cost-effectiveness analysis (CEA) can provide valuable information for decision-makers when deciding whether to use these high-priced medications. Many CEAs on OAMs have been conducted using various analytical approaches and cost-effectiveness thresholds (CETs). However, there is no comprehensive ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 16, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Conclusion: Adjuvant therapy using S-1 is a cost-effective alternative compared to gemcitabine in patients with postoperative pancreatic cancer from the Chinese societal perspective. PMID: 31597496 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 11, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost analysis of potentially inappropriate medication in older hospitalised patients.
Conclusions: The current study assessed the prevalence of potentially inappropriate medications in older hospitalised patients and established that their substitution by alternative medications provided a cost saving. PMID: 31595794 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 10, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The economic burden of Chronic Obstructive Pulmonary Disease (COPD) in USA, Europe and Asia: results from a systematic review of the literature.
Conclusion: Limiting the disease to early stage and preventing exacerbations may reduce the cost of management of COPD. PMID: 31596632 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 10, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Disease activity and sleep quality in rheumatoid arthritis: A deeper look into the relationship.
This study looks deeper into the relationship between rheumatoid arthritis (RA) disease activity and distinct dimensions of sleep quality. Methods: The Pittsburgh Sleep Quality Index (PSQI) was administered to a cohort of 147 RA patients. Health-related quality of life (HRQoL) and fatigue were measured with the SF-12 and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) instruments respectively, whereas RA activity was determined with the Disease Activity Score 28 joints (DAS28). Ethical approval for the study and informed consent from the participants were obtained. Results: Most patients were females (78...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 9, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Psychometric assessment of the health-related productivity questionnaire (HRPQ) among women with endometriosis.
Conclusion: The HRPQ is a valid and responsive tool for evaluating patient-reported productivity at work and at home among women with endometriosis. PMID: 31530044 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 20, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary.
Conclusion: Policy tools and measures should be developed to facilitate first-line use of multisource biologicals for treatment naive patients and promoting use of more affordable multisource biologicals in case of switching. PMID: 31510811 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 14, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Measuring quality of life in COPD patients: comparing disease-specific supplements to the EQ-5D-5L.
Conclusion: CAT outperformed CCQ and SGRQ, and it increased the explanatory power of VAS. EBV combined with CAT seems superior to only generic or disease-specific approaches. PMID: 31512524 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 14, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Economic consequences of the implementation of national screening program for chronic HCV infection.
Conclusions: Targeted testing among adults between 39 and 64 years with anti-HCV antibody once per their life in Bulgaria could be considered as cost-effective and provides benefits both for the paying institutions and the patients. PMID: 31514552 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 14, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Economic evaluation of a home-based programme to reduce concerns about falls in frail, independently-living older people.
Discussion The programme is likely to be cost-effective, and therefore a useful addition to current geriatric care, particularly for those persons who are not able or willing to attend group programmes. Trial registration: NCT01358032. PMID: 31502897 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 12, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan.
Conclusion: As Japan's CEE is expected to be used only for price adjustment after reimbursement is secured, the approach seems to be similar to the other countries. However, pre-launch clinical data are limited and the peak sales of ODs vary in Japan. Therefore, careful introduction of CEE and multifaceted measures referring the policies for ODs in other countries should be considered. PMID: 31496361 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 10, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research